AFT Pharmaceuticals Limited Analysis

Overview

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

Performance

The following information was extracted from AFT Pharmaceuticals Limited's market update, released on 7 July 2026:

HIGHLIGHTS

• On track to reach $300 million FY27 revenue target, with longer term growth supported by a full product launch pipeline
• Novel iron injectable product passes US and Japanese regulatory hurdles
• R&D pipeline further strengthened with execution of an option agreement for a novel injectable formulation in a significant market estimated to exceed US$3 billion by 2032-4

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company2, today announces sustained growth in the first quarter of the 2027 financial year. It remains on track to reach its $300 million FY27 annual revenue target. AFT Managing Director Dr Hartley Atkinson said: “We are pleased with our quarterly sales progress and the advances we have made in our R&D pipeline of, now, eight patented products that together offer the potential of significant long-term value to the business.”